NICE turns down AZ’ Faslodex for breast cancer
admin 1st September 2017 Uncategorised 0It is looking unlikely that AstraZeneca’s breast cancer drug Faslodex will be routinely funded on the NHS to delay growth of a specific type of breast cancer, after cost regulators concluded that its benefit over existing therapies has not been shown at this time.
More: NICE turns down AZ’ Faslodex for breast cancer
Source: News